# Proof of Principle Study Evaluating Gonyautoxins NEURO SERUM, on Chemotherapy-induced Peripheral Neuropathy

> **NCT05052398** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Algenis SpA** · enrollment: 52 (estimated)

## Conditions studied

- Chemotherapy-induced Peripheral Neuropathy

## Interventions

- **DRUG:** PSP NEURO SERUM
- **DRUG:** Placebo PSP NEURO SERUM

## Key facts

- **NCT ID:** NCT05052398
- **Lead sponsor:** Algenis SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-14
- **Primary completion:** 2024-07-11
- **Final completion:** 2025-07-14
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2024-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05052398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05052398, "Proof of Principle Study Evaluating Gonyautoxins NEURO SERUM, on Chemotherapy-induced Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05052398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*